
Imagine your metabolism as a bustling city. For decades, scientists thought keeping traffic moving was simply a matter of sending the right messengers across town. Hormones dispatched from the gut would knock on specific cell doors, deliver an instruction, and move on.
That tidy picture is becoming far more nuanced. Researchers are looking closely at how three gut-derived sibling molecules—GLP-1, GLP-2, and the elusive GLP-3—interact with cellular docking stations. At the same time, they are pairing that knowledge with an entirely different kind of molecule: SS-31, a synthetic peptide that slips straight past the cell door to tune the city’s power plants.
By studying these receptor-targeted signals alongside direct cellular energy modulators, scientists are piecing together a much richer map of metabolic control.
What Are GLP-1, GLP-2, and GLP-3?
All three peptides originate from the exact same genetic blueprint: the proglucagon gene. Inside specialized cells, enzymes snip this parent protein into distinct fragments, producing mature peptides with vastly different biological jobs.
- **GLP-1 (Glucagon-like Peptide 1):** The best-known sibling, recognized for regulating blood sugar. When food enters the system, GLP-1 prompts pancreatic beta cells to release insulin, suppresses glucagon, slows stomach emptying, and signals satiety to the brain.
- **GLP-2 (Glucagon-like Peptide 2):** Rather than handling blood glucose, GLP-2 directs gut maintenance. It stimulates the lining of the intestine, supporting nutrient absorption, deepening intestinal crypts, and maintaining a robust gut barrier.
- **GLP-3 (Glucagon-like Peptide 3):** The newest and least understood sibling. While it appears to have a hand in metabolic balance, it remains an emerging puzzle in metabolic laboratories.
In their natural forms, these peptides are fragile. An enzyme called dipeptidyl peptidase-4 (DPP-4) rapidly dismantles them in living tissue, meaning their native signals are brief flashes rather than sustained broadcasts.
How SS-31 Works Differently
While the GLP family acts like external couriers ringing doorbells, SS-31 takes an entirely different route. It is a synthetic, cell-penetrating peptide that completely bypasses cell-surface receptors.
Instead, SS-31 heads straight for the inner membrane of the mitochondria—the microscopic energy generators inside cells. Once there, it docks onto a specialized lipid called cardiolipin.
Cardiolipin keeps the inner mitochondrial machinery organized. By shielding this delicate lipid from oxidative damage and stabilizing it, SS-31 prevents electrons from leaking out of the energy transport chain. In simple terms: it quietens reactive oxygen species (cellular "rust") and helps the engine run smoothly, producing steady cellular energy (ATP).
Receptor Selectivity: The Molecular Handshakes
Cells use specific surface docking ports known as G-protein coupled receptors (GPCRs) to listen to hormonal cues. When a peptide docks, it triggers a spike in an internal messenger molecule called cyclic adenosine monophosphate (cAMP), setting off a chain reaction.

GLP-1 and the GLP-1 Receptor GLP-1 docks precisely into the GLP-1 receptor (GLP1R), found on pancreatic beta cells, in the brain, the gut, and kidneys. Triggering this pathway activates internal enzymes (PKA and PKC) that promote insulin release when glucose is present, support beta-cell survival, and dial down hunger signals in rodent models.
GLP-2 and the GLP-2 Receptor GLP-2 binds to its own dedicated port, GLP2R, which sits primarily in the digestive tract—on gut lining cells, enteric nerves, and endocrine cells. Here, the resulting cAMP signal prompts epithelial cells to multiply and resist cell death, shielding intestinal tissue against wear and tear.
The Mystery of GLP-3 GLP-3 is where things get complicated. Scientists have not yet confirmed a dedicated, high-affinity receptor for it across species.
In laboratory dish assays, GLP-3 can influence insulin and glucagon, but often with less potency than GLP-1. Researchers suspect it may act as a partial agonist or antagonist at the GLP-1 or GLP-2 receptors, or perhaps influence metabolism through indirect pathways that are yet to be mapped.
| Feature | GLP-1 | GLP-2 | GLP-3 | SS-31 |
|---|---|---|---|---|
| **Primary Target** | GLP1R (surface GPCR) | GLP2R (surface GPCR) | Undefined (investigational) | Inner mitochondrial membrane (cardiolipin) |
| **Main Action** | Glucose regulation, satiety | Gut lining growth, barrier integrity | Subtle metabolic modulation | Reduces oxidative stress, stabilizes energy |
| **Primary Tissues** | Pancreas, brain, GI tract | Intestines, enteric nervous system | Pancreas, gut | Mitochondria across various tissues |
| **Mechanism** | cAMP / PKA signaling | cAMP-driven cell renewal | Under active study | Direct bioenergetic stabilization |
What Does the Research Actually Explore?
Decades of laboratory and animal studies have slowly built our understanding of these distinct pathways:
- **GLP-1 Milestones:** Early rodent experiments in the 1980s and 1990s confirmed GLP-1's direct effect on insulin. Later studies in metabolic models and primates examined long-acting analogues, tracing how extended receptor engagement alters body weight, glucose handling, and brain tissue protection.
- **GLP-2 and Intestinal Repair:** Landmark work in the 1990s revealed GLP-2 increased villus height in rodent guts. Subsequent animal models of short bowel syndrome and inflammatory bowel disease demonstrated its capacity to reduce gut damage and encourage nutrient absorption.
- **Emerging GLP-3 Trials:** Isolated pancreatic islet experiments from the 2000s onward showed modest shifts in insulin release. Meanwhile, rodent experiments have hinted at subtle changes in energy expenditure and satiety, though results vary depending on experimental setups.
- **SS-31 in Bioenergetics:** Since its discovery in the early 2000s, SS-31 has been tested in animal models of metabolic syndrome, aging, and ischemia-reperfusion injury (tissue damage caused when blood supply returns after a shortage). Across these models, electron microscopy and respiration tests showed reduced oxidative stress and preserved mitochondrial structure.
Important Things to Understand
Because these compounds are active subjects of laboratory research, several gaps and complexities remain:
- **Receptor Cross-Talk:** Because GLP-3's target is unconfirmed, lab models must carefully separate its effects from potential background interactions with GLP-1 or GLP-2 receptors.
- **Species Variations:** Rodent metabolic pathways and receptor distributions do not mirror human biology identically. Findings in animal models cannot be assumed to translate directly.
- **Cellular Delivery:** While SS-31 successfully enters mitochondria in lab settings, researchers are still mapping how evenly it reaches different tissue types, such as brain versus liver mitochondria.
- **Lab-Only Handling:** All four peptides are strictly experimental research tools, not approved consumer products or medicines. Because peptide chains degrade easily, experimental models require rigorous purity checks, like mass spectrometry and high-performance liquid chromatography, to prevent degraded fragments from distorting findings.
By examining both the external messengers that instruct cells and the internal power plants that keep them alive, scientists are uncovering how metabolic health is orchestrated from the cell surface down to the mitochondrial core.
Further reading on Peptide Intel Hub: verified research suppliers, how to read a certificate of analysis, every protocol from A to Z.
Quick questions, clear answers
What is the main difference between GLP-1, GLP-2, and GLP-3?+
GLP-1 primarily regulates glucose and satiety via the GLP-1 receptor, while GLP-2 focuses on gut barrier integrity and intestinal cell growth via the GLP-2 receptor. GLP-3 is an emerging peptide whose exact receptor mechanisms are still being mapped.
How does SS-31 differ from GLP peptides?+
Unlike GLP peptides that dock onto cell-surface receptors, SS-31 is a cell-penetrating peptide that travels straight to the inner mitochondrial membrane. It binds to cardiolipin, helping to reduce oxidative stress and stabilize cellular energy production.
Has a specific receptor been discovered for GLP-3?+
Scientists have not yet identified a confirmed, dedicated receptor for GLP-3 across species. Research models suggest it may act as a partial agonist or antagonist at GLP-1 or GLP-2 receptors, or operate via indirect metabolic pathways.
Keep reading
More in Weight Management & Metabolic Research

Incretin Peptide Agonists: Single, Dual and Triple
From single GLP-1 targets to dual and triple agonists, explore how multi-receptor incretin peptides are reshaping metabolic science in the laboratory.
Apelin: The Multitasking Peptide of Metabolic Science
Explore apelin, the multitasking endogenous peptide and adipokine connecting heart health, water balance, and glucose metabolism across cellular pathways.

Semaglutide vs Tirzepatide: A Research Comparison
A research-grade comparison of semaglutide and tirzepatide, examining selective GLP-1 targeting versus dual GIP/GLP-1 agonism in laboratory models.
Related guides & studies
GLP-1 research worldwide
How peptide research is regulated and discussed in each region we cover.
References & clinical studies
No identified primary paper is recorded for this overview. Use the discovery links below to locate original studies; a search is not a citation or confirmation of the claims on this page.
